Health Care · Surgical & Medical Instruments & Apparatus

LMAT LEMAITRE VASCULAR INC SEC Filings & Insider Trading Activity 2026

company
CIK 1158895143 filings
Russell 2000

LMAT at a glance

LEMAITRE VASCULAR INC (LMAT, SEC CIK 1158895) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), LEMAITRE VASCULAR INC (LMAT) reported revenue of $249.6 million (up 13.5% from FY2024) and net income of $57.7 million. Diluted EPS was $2.52.
  • As of September 30, 2026, 30 institutional investment managers tracked by SignalX reported holding LEMAITRE VASCULAR INC (LMAT) shares worth $861.6 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$249.6M
+13.5% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
30 funds
$861.6M · −3 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business model: global medical devices and human tissue cryopreservation services focused on treating peripheral vascular, end-stage renal, and cardiovascular diseases
  • New product emphasis: launch of PhasTIPP Powered Phlebectomy System in US (H1 2024) and marketing of Artegraft biologic graft in EU after April 2025 CE mark approval
  • Strategic shift: increased focus on adjacent cardiac surgeon market and expanded direct sales force (160 reps as of 12/31/2025) covering 95% of net sales
  • Notable metric: biologic product sales represent 53% of total revenues in 2025, up from 51% in 2023; sales force steady at 160 representatives globally
  • Unique fact: FDA issued warning letter in August 2025 on North Brunswick facility following April audit; company addressed eight observations, pending reinspection

Risk Factors

  • Regulatory risk: ASC 606 revenue recognition standard requires judgment in estimating sales returns, impacting reported revenue and allowances
  • Macroeconomic threat: $9.1 million inventory purchase commitments expose business to supply cost fluctuations through 2026
  • Operational vulnerability: inventory write-offs provisioning driven by product expiration and inaccurate future demand forecasts affect margins
  • Market disruption risk: contingent consideration liabilities from acquisitions subject to performance criteria remeasured quarterly affect earnings volatility
  • Financial risk: $167.8 million net proceeds from 2024 Convertible Notes issuance increase leverage and interest expense exposure

Management Discussion & Analysis

  • Revenue $249.6M in 2025, up 14% YoY (+$29.7M from $219.9M in 2024) with highest growth in EMEA (+22%, +$13.2M)
  • Gross margin 71.5% in 2025 vs 68.6% in 2024, up 290bps; driven by Employee Retention Credit, manufacturing efficiencies, and price increases
  • Best segment EMEA net sales +$13.2M (22%); worst impact from product line wind-downs totaling ~$3M in 2025 revenues
  • Cash and equivalents $28.2M (+$2.6M), short-term marketable securities $330.9M (+$56.8M); new $100M share repurchase authorized, no buys yet
  • Management highlights growth via sales force expansion, acquisitions (e.g., Andramed for $1.8M), and new regulatory approvals; risks include product transitions and foreign exchange impacts

AI summary of the LMAT 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly updated regulatory risk: FDA re-inspection of Artegraft facility identified additional observations in June 2026
  • Most material compliance risk: FDA may impose enforcement actions if corrective actions addressing the August 2025 warning letter prove unsatisfactory
  • Product liability risk: Recalls or defects could trigger significant costs, adverse publicity, and claims
  • Operational risk: Ongoing Artegraft remediation requires management resources and may affect operations or sales
  • Financial risk: Foreign currency exposure affected approximately 45% of sales outside the United States

Management Discussion & Analysis

  • Revenue $68.0M, up 11% YoY from $61.0M, driven by graft sales increasing $4.5M
  • Gross margin 71.7% vs 75.3% YoY, affected by 2025 ERC and $0.5M PhasTIPP excess charges
  • EMEA strongest geography, revenue up 18% to $20.8M; APAC weakest, up 5% to $4.4M
  • Cash $27.5M vs $28.2M at December 31, 2025; short-term securities increased to $362.2M
  • Operating cash flow $53.0M vs $58.1M YoY; dividends paid $17.1M and capital expenditures $7.4M

AI summary of the LMAT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Preliminary financial and operational results announced for quarter ended September 30, 2026
  • Investors should review Exhibit 99.1 for the company’s reported quarterly figures and operating updates

Item EX-99.1: Item EX-99.1

  • Q3 sales $68.0mm, up 11% reported and 12% organically, led by grafts up 20% and shunts up 14%
  • GAAP EPS $0.65, down 14%, but adjusted EPS $0.65, up 5% after excluding the 2025 tax-credit benefit
Filed Oct 15, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • President David B. Roberts retiring effective December 31, 2026 after 29 years of executive service
  • Roberts will remain a director through his 2029 term, preserving leadership continuity and institutional knowledge
Filed Aug 4, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 sales $70.4mm, up 10% organically, with organic growth reaching 12% excluding catheters
  • Gross margin expanded 210 bps to 72.1%; operating income rose 26% to $20.4mm

Item 2.02: Results of Operations and Financial Condition

  • Preliminary financial and operational results for quarter ended June 30, 2026 announced August 4, 2026
  • Investors should review Exhibit 99.1 for revenue, profitability and operating metrics

AI summaries of LMAT 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for LMAT

Don't miss the next LMAT filing

  • Alerts as it files. A push when LMAT files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut LMAT, by share count.
  • Ask anything. An AI agent that reads every LMAT filing and answers with sources.

LMAT alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
O'Connor John JamesMNov 18, 2026$48.60
O'Connor John JamesMNov 18, 2026-
Roush John AASep 3, 2026-
Roush John AASep 3, 2026-
Roush John AASep 3, 2026-
Jasinski Lawrence JASep 3, 2026-
Jasinski Lawrence JASep 3, 2026-
Jasinski Lawrence JASep 3, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$219.9M$249.6M
Gross Profit-$150.9M$178.5M
Operating Income-$52.3M$67.9M
Net Income$30.1M$44.0M$57.7M
Gross Margin-68.6%71.5%
Op. Margin-23.8%27.2%
Net Margin-20.0%23.1%
Balance Sheet
Total Assets-$551.8M$615.7M
Equity$297.9M$337.3M$393.5M
ROE10.1%13.1%14.7%
Per Share
EPS$1.34$1.93$2.52
Cash Flow
Operating CF$36.8M$44.1M$81.3M

Source: XBRL data in LEMAITRE VASCULAR INC (LMAT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate LMAT share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
LMAT shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202630$861.6M
Q2 202633$972.2M
Q1 202633$1.03B
Q4 202530$724.9M
Q3 202531$786.0M
Q2 202532$750.9M
Q1 202530$467.4M
Q4 202428$425.7M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 247 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

LMAT filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 20, 2026--
10-QNov 5, 2026Analysis
8-KNov 4, 2026Analysis-
8-KOct 15, 2026Analysis-
4Sep 8, 2026--
4Sep 8, 2026--
4Sep 8, 2026--
4Sep 8, 2026--
4Sep 8, 2026--
4Sep 8, 2026--
4Sep 8, 2026--
4Sep 8, 2026--
4Sep 8, 2026--
4Sep 3, 2026--
10-QAug 5, 2026Analysis
8-KAug 4, 2026Analysis-
SC 13GJul 27, 2026-
4Jun 5, 2026-
8-KJun 5, 2026Analysis
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-

Related Health Care companies

All Health Care →

LMAT SEC filings: frequently asked questions

Which institutions hold LMAT stock?

As of September 30, 2026, the largest LEMAITRE VASCULAR INC (LMAT) holders among the 13F filers tracked by SignalX were BlackRock ($276.3 million), T. Rowe Price Group ($80.9 million), Vanguard Capital Management LLC ($79.2 million), State Street Corp ($75.0 million), Vanguard Portfolio Management LLC ($50.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was LMAT's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), LEMAITRE VASCULAR INC (LMAT) reported revenue of $249.6 million (up 13.5% from FY2024) and net income of $57.7 million. Diluted EPS was $2.52. The figures come from the XBRL data in the 10-K.

What are the main risks in LMAT's latest 10-K?

In the 10-K filed February 26, 2026, LEMAITRE VASCULAR INC (LMAT) flagged: Regulatory risk: ASC 606 revenue recognition standard requires judgment in estimating sales returns, impacting reported revenue and allowances. Macroeconomic threat: $9.1 million inventory purchase commitments expose business to supply cost fluctuations through 2026. (AI summary of the Risk Factors section.)

What did LMAT report in its latest 8-K?

LEMAITRE VASCULAR INC (LMAT) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Preliminary financial and operational results announced for quarter ended September 30, 2026.

What are the latest LMAT SEC filings?

LEMAITRE VASCULAR INC (LMAT) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 20, 2026.

What is LMAT's SEC CIK number?

LEMAITRE VASCULAR INC (LMAT)'s SEC Central Index Key (CIK) is 1158895. EDGAR lists every LMAT filing under that number.

Ask anything about LMAT

The research agent reads LMAT's filings, financials, insider trades and 13F holders, then answers with sources.